Nanoviricides, Inc. (NNVC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Nanoviricides reported revenue of $0. Net income was -$8.2M, or -$0.41 per diluted share. Operating activities generated -$7.7M of cash, leaving -$7.8M of free cash flow. At fiscal year end, Nanoviricides held $9.9M in total assets against $1.2M in total liabilities, including $2.8M of cash and equivalents.
Open the full interactive Nanoviricides financials → Quarterly statements, key ratios, valuation history and price charts.
Nanoviricides Key Stats
| Share Price | $1.32 |
|---|---|
| Market Cap | $26.6M |
| 52-Week Range | $0.85 – $2.03 |
| Shares Outstanding | 20.2 million (basic, 2026 Q4) |
Nanoviricides Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$8.7M | -$8.1M | -$8.9M | -$8.5M | -$9.6M | -$8.3M |
| Pre-Tax Income | -$8.8M | -$8.1M | -$8.6M | -$8.3M | -$9.5M | -$8.2M |
| Net Income | -$8.8M | -$8.1M | -$8.6M | -$8.3M | -$9.5M | -$8.2M |
| Diluted EPS | -$0.81 | -$0.70 | -$0.74 | -$0.70 | -$0.63 | -$0.41 |
Nanoviricides Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.8M | -$2.2M | -$2.0M | -$2.2M |
| Diluted EPS | -$0.10 | -$0.11 | -$0.09 | -$0.11 |
Nanoviricides Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.5M | $14.1M | $8.1M | $4.8M | $1.6M | $2.8M |
| Current Assets | $20.8M | $14.4M | $8.4M | $5.0M | $1.7M | $3.2M |
| Total Assets | $30.3M | $23.5M | $16.9M | $12.8M | $8.8M | $9.9M |
| Current Liabilities | $351,146 | $412,837 | $534,250 | $1.4M | $1.3M | $1.2M |
| Total Long-Term Debt | $95,306 | $94,788 | — | — | — | — |
| Total Liabilities | $351,146 | $412,837 | $2.0M | $1.4M | $1.3M | $1.2M |
| Shareholders' Equity | $29.9M | $23.1M | $14.9M | $11.5M | $7.5M | $8.7M |
Nanoviricides Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$8.2M | -$5.9M | -$5.7M | -$6.3M | -$8.5M | -$7.7M |
| Cash From Investing | — | — | -$151,712 | -$156,560 | -$56,964 | -$84,317 |
| Cash From Financing | $15.3M | -$234,716 | -$94,788 | $3.1M | $5.3M | $9.0M |
| Free Cash Flow | -$8.4M | -$6.2M | -$5.9M | -$6.5M | -$8.6M | -$7.8M |
Figures from Nanoviricides' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Nanoviricides financials page for every line item.
Nanoviricides Company Profile
| Ticker | NNVC |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Shelton, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001379006 |
Frequently Asked Questions
What was Nanoviricides' revenue in fiscal 2026?
Nanoviricides (NNVC) reported revenue of $0 for fiscal 2026.
What is Nanoviricides' annual revenue history?
Nanoviricides' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0; 2026: $0.
What was Nanoviricides' net income in fiscal 2026?
Nanoviricides reported net income of -$8.2M for fiscal 2026.
What was Nanoviricides' earnings per share (EPS) in fiscal 2026?
Nanoviricides' diluted EPS was -$0.41 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Nanoviricides generate in fiscal 2026?
Nanoviricides generated -$7.8M of free cash flow in fiscal 2026.
What was Nanoviricides' revenue last quarter?
In its most recent reported quarter (2026 Q4), Nanoviricides reported revenue of $0.
How many shares of Nanoviricides are outstanding?
Nanoviricides reported a weighted average of 20.2 million basic shares outstanding in 2026 Q4.
What is Nanoviricides' market cap?
Based on its latest closing price, Nanoviricides (NNVC) has a market capitalization of about $26.6M.
When does Nanoviricides' fiscal year end?
Nanoviricides' fiscal year end, as registered with the SEC, is June 30.
Where is Nanoviricides headquartered?
Nanoviricides lists its business address in Shelton, Connecticut in its SEC filings.